Increased Competition for Big Pharma in Late-Stage Licensing?
Do in-licensing-focused specialty pharmas spell tougher competition for Big Pharma, traditionally the biggest customer for late-stage product licenses?
You may also be interested in...
A closer look at the trend in biotech (top tier, and others) and specialty pharma in-licensing of clinical stage products.
There is speculation that it is the end of the road for abicipar pegol but Allergan has declined to say whether this is the case for the product that has been in development for wet AMD.